Explore the pharmaceutical companies that develop sparsentan/sparsentan

Sparsentan/SparsentanThis innovative drug brings new hope to patients with primary immunoglobulin A nephropathy (IgAN) with its unique once-daily oral non-immunosuppressive therapy. Especially for those high-risk adult patients with rapidly worsening disease and urine protein/creatinine ratio (UPCR) ≥1.5g/g, sparsantanehas demonstrated significant efficacy. Its pharmaceutical form is 200mg and 400mg white to off-white film-coated modified oval tablets with the trade name Filspari, which has already occupied a certain position in the market.

Sparsentanis developed by Travere Therapeutics, a leader in the U.S. biopharmaceutical field, together with its partner Ligand Pharmaceuticals. As the first single-molecule dual endothelin angiotensin II receptor antagonist (DEARA), it precisely targets endothelin-1 and angiotensin II, two key pathways leading to disease progression, thereby achieving effective treatment of the disease. In September 2021, Swiss pharmaceutical giant Vifor Pharma (now merged into CSL Vifor) obtained commercial licenses to develop spaxentan in Europe, Australia and New Zealand. This is undoubtedly a strong recognition of the international market potential of the drug.

The U.S. Food and Drug Administration (FDA) approved sparsenstat based on its excellent performance in the pivotal PROTECT clinical trial. The results of this largest face-to-face intervention study in the field of IgAN to date show that sparsentan achieved clinically meaningful and statistically significant results in reducing proteinuria compared with the control drug irbesartan. Specifically, proteinuria levels decreased by an average of 49.8% from baseline at week 36 among patients who received sparsentan, compared with only a 15.1% decrease among patients in the irbesartan group. Currently, these patients are still in the follow-up phase of the PROTECT study, where treatment effects are assessed in a blinded manner for up to 110 weeks, focusing on changes in estimated glomerular filtration rate (eGFR) slope.